Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Collaboration Centers Around Discipher System

By Drug Discovery Trends Editor | April 9, 2012

LingVitae, Plarion Ltd, and KTH Royal Institute of Technology have announced engagement into a collaborative development program aiming at utilizing the Discipher system for bringing DNA-based testing and diagnostics to point-of-care settings.

“Our aim with the Discipher is to democratize molecular and cellular analysis, putting low-cost, easy-to-use tools in the hands of the wider community, outside of core laboratories”, said Dr. Jackie Cole, head of marketing for Plarion.

As part of this engagement with KTH, LingVitae/Plarion will transfer prototype versions of the Discipher instrument to the researchers at KTH, as well as supporting the development work by customising the optical disc-based disposable assay devices.

“We look forward to the collaboration with Professor Lundeberg’s group. The track-record of KTH on development of DNA based assays, utilising a repertoire of molecular techniques, provides an exciting opportunity for us to expand our activities in the DNA assay space”, says Dr. Preben Lexow, Chief Executive Officer of LingVitae.

Discipher is a low-cost, walk-away system, based on DVD technology. It uses self-contained, disposable assay devices in the form of DVD discs with microfluidic channels. The system has been jointly developed by UK-based Plarion Ltd and LingVitae, a Scandinavian life science company. This work has been supported by funding from the Seventh Research Framework Program of the European Union, under the Digital Sequencing project (contract 222913).

“We see that the Discipher system addresses an unmet need in bringing DNA-based diagnostics and testing to users who have previously had not access to this technology. We look forward the opportunity to strengthen our collaboration with both LingVitae and Plarion”, says Professor Lundeberg, based at the Science for Life Laboratory in Stockholm.

Date: March 29, 2012
Source: LingVitae Corporation


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE